PDB Short entry for 2X2C HEADER ISOMERASE/IMMUNOSUPPRESSANT 12-JAN-10 2X2C TITLE ACETYL-CYPA:CYCLOSPORINE COMPLEX COMPND MOL_ID: 1; COMPND 2 MOLECULE: CYCLOSPORIN A; COMPND 3 CHAIN: B, F, L, P, R; COMPND 4 SYNONYM: CICLOSPORIN, CICLOSPORINE; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: PEPTIDYL-PROLYL CIS-TRANS ISOMERASE A; COMPND 8 CHAIN: K, M, O, Q, S; COMPND 9 SYNONYM: PPIASE A, ROTAMASE A, CYCLOPHILIN A, CYCLOSPORIN A-BINDING COMPND 10 PROTEIN, CYPA; COMPND 11 EC: 5.2.1.8; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: TOLYPOCLADIUM INFLATUM; SOURCE 4 ORGANISM_TAXID: 29910; SOURCE 5 MOL_ID: 2; SOURCE 6 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 7 ORGANISM_COMMON: HUMAN; SOURCE 8 ORGANISM_TAXID: 9606; SOURCE 9 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 10 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS ISOMERASE-IMMUNOSUPPRESSANT COMPLEX, CYCLOPHILIN-CYCLOSPORIN COMPLEX, KEYWDS 2 CYCLOSPORIN A, IMMUNOSUPPRESSANT, ISOMERASE EXPDTA X-RAY DIFFRACTION AUTHOR M.LAMMERS,H.NEUMANN,J.W.CHIN,L.C.JAMES REVDAT 5 02-MAY-18 2X2C 1 REMARK REVDAT 4 26-OCT-11 2X2C 1 JRNL REVDAT 3 13-JUL-11 2X2C 1 VERSN REVDAT 2 14-APR-10 2X2C 1 KEYWDS REVDAT 1 23-MAR-10 2X2C 0 JRNL AUTH M.LAMMERS,H.NEUMANN,J.W.CHIN,L.C.JAMES JRNL TITL ACETYLATION REGULATES CYCLOPHILIN A CATALYSIS, JRNL TITL 2 IMMUNOSUPPRESSION AND HIV ISOMERISATION JRNL REF NAT.CHEM.BIOL. V. 6 331 2010 JRNL REFN ISSN 1552-4450 JRNL PMID 20364129 JRNL DOI 10.1038/NCHEMBIO.342 REMARK 2 REMARK 2 RESOLUTION. 2.41 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0109 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.41 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 61.27 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 3 NUMBER OF REFLECTIONS : 54725 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.209 REMARK 3 R VALUE (WORKING SET) : 0.206 REMARK 3 FREE R VALUE : 0.264 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 2928 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.41 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.47 REMARK 3 REFLECTION IN BIN (WORKING SET) : 3644 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 91.92 REMARK 3 BIN R VALUE (WORKING SET) : 0.2570 REMARK 3 BIN FREE R VALUE SET COUNT : 212 REMARK 3 BIN FREE R VALUE : 0.3150 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 6770 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 497 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 27.34 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.06000 REMARK 3 B22 (A**2) : -0.06000 REMARK 3 B33 (A**2) : 0.09000 REMARK 3 B12 (A**2) : -0.03000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.270 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.236 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.166 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 7.077 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.925 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.881 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 6895 ; 0.020 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 4745 ; 0.004 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 9250 ; 1.759 ; 1.977 REMARK 3 BOND ANGLES OTHERS (DEGREES): 11475 ; 0.984 ; 3.002 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 830 ; 7.082 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 295 ;34.620 ;24.237 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1105 ;16.741 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 30 ;17.901 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 985 ; 0.103 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 7670 ; 0.007 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 1405 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 4330 ; 0.868 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 1820 ; 0.181 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 6895 ; 1.643 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 2565 ; 2.492 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 2355 ; 4.069 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 5 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : K 1 K 165 REMARK 3 ORIGIN FOR THE GROUP (A): 37.4600 11.5210 -31.3920 REMARK 3 T TENSOR REMARK 3 T11: 0.3430 T22: 0.1420 REMARK 3 T33: 0.2635 T12: 0.0606 REMARK 3 T13: 0.0563 T23: 0.0271 REMARK 3 L TENSOR REMARK 3 L11: 2.1122 L22: 2.3265 REMARK 3 L33: 1.8915 L12: -0.2906 REMARK 3 L13: 0.0612 L23: 0.1227 REMARK 3 S TENSOR REMARK 3 S11: 0.0110 S12: -0.0431 S13: 0.3239 REMARK 3 S21: 0.1113 S22: 0.0146 S23: 0.1337 REMARK 3 S31: -0.2956 S32: -0.0666 S33: -0.0256 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : M 1 M 165 REMARK 3 ORIGIN FOR THE GROUP (A): 13.1110 -12.0290 -16.4170 REMARK 3 T TENSOR REMARK 3 T11: 0.2672 T22: 0.3012 REMARK 3 T33: 0.2940 T12: 0.0864 REMARK 3 T13: 0.1030 T23: 0.0565 REMARK 3 L TENSOR REMARK 3 L11: 2.0151 L22: 1.9539 REMARK 3 L33: 1.7841 L12: 0.1364 REMARK 3 L13: -0.0997 L23: 0.1836 REMARK 3 S TENSOR REMARK 3 S11: 0.0101 S12: -0.0673 S13: 0.1972 REMARK 3 S21: 0.1472 S22: -0.0529 S23: 0.3822 REMARK 3 S31: -0.1719 S32: -0.3755 S33: 0.0428 REMARK 3 REMARK 3 TLS GROUP : 3 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : O 1 O 165 REMARK 3 ORIGIN FOR THE GROUP (A): 31.3650 -43.1950 -8.1800 REMARK 3 T TENSOR REMARK 3 T11: 0.0804 T22: 0.1258 REMARK 3 T33: 0.0575 T12: -0.0146 REMARK 3 T13: 0.0585 T23: 0.0306 REMARK 3 L TENSOR REMARK 3 L11: 2.0573 L22: 2.2103 REMARK 3 L33: 2.3588 L12: 0.1704 REMARK 3 L13: -0.2761 L23: -0.5926 REMARK 3 S TENSOR REMARK 3 S11: 0.0102 S12: -0.0275 S13: 0.0123 REMARK 3 S21: 0.0358 S22: 0.0815 S23: 0.0738 REMARK 3 S31: -0.0177 S32: -0.0794 S33: -0.0916 REMARK 3 REMARK 3 TLS GROUP : 4 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : Q 1 Q 165 REMARK 3 ORIGIN FOR THE GROUP (A): 66.6260 -39.1690 -18.0440 REMARK 3 T TENSOR REMARK 3 T11: 0.0634 T22: 0.0764 REMARK 3 T33: 0.0210 T12: -0.0302 REMARK 3 T13: -0.0120 T23: 0.0317 REMARK 3 L TENSOR REMARK 3 L11: 2.6925 L22: 2.5211 REMARK 3 L33: 1.8694 L12: -0.2912 REMARK 3 L13: 0.5527 L23: -0.1954 REMARK 3 S TENSOR REMARK 3 S11: 0.0559 S12: -0.0631 S13: -0.0456 REMARK 3 S21: 0.1391 S22: -0.0250 S23: -0.0866 REMARK 3 S31: 0.0674 S32: 0.0938 S33: -0.0309 REMARK 3 REMARK 3 TLS GROUP : 5 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : S 1 S 165 REMARK 3 ORIGIN FOR THE GROUP (A): 70.4980 -5.1970 -32.2890 REMARK 3 T TENSOR REMARK 3 T11: 0.1887 T22: 0.0637 REMARK 3 T33: 0.1012 T12: -0.0646 REMARK 3 T13: -0.0231 T23: 0.0153 REMARK 3 L TENSOR REMARK 3 L11: 2.5784 L22: 2.4292 REMARK 3 L33: 1.9869 L12: 0.3279 REMARK 3 L13: -0.0367 L23: -0.2205 REMARK 3 S TENSOR REMARK 3 S11: -0.0050 S12: -0.0692 S13: 0.1568 REMARK 3 S21: 0.0741 S22: 0.0010 S23: -0.1484 REMARK 3 S31: -0.2582 S32: 0.2020 S33: 0.0040 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2X2C COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 12-JAN-10. REMARK 100 THE DEPOSITION ID IS D_1290042444. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 287 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID29 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 58013 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 57.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 200 DATA REDUNDANCY : 3.200 REMARK 200 R MERGE (I) : 0.15000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 5.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 66.77 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.70 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 61 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+5/6 REMARK 290 6555 X-Y,X,Z+1/6 REMARK 290 7555 Y,X,-Z+1/3 REMARK 290 8555 X-Y,-Y,-Z REMARK 290 9555 -X,-X+Y,-Z+2/3 REMARK 290 10555 -Y,-X,-Z+5/6 REMARK 290 11555 -X+Y,Y,-Z+1/2 REMARK 290 12555 X,X-Y,-Z+1/6 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 142.95700 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 285.91400 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 214.43550 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 357.39250 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 71.47850 REMARK 290 SMTRY1 7 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 7 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 142.95700 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 9 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 9 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 9 0.000000 0.000000 -1.000000 285.91400 REMARK 290 SMTRY1 10 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 10 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 10 0.000000 0.000000 -1.000000 357.39250 REMARK 290 SMTRY1 11 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 11 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000 214.43550 REMARK 290 SMTRY1 12 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 12 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 12 0.000000 0.000000 -1.000000 71.47850 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: EICOSAMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: EICOSAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 27350 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 62040 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -185.8 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, F, K, L, M, O, P, Q, R, S REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 0.500000 -0.866025 0.000000 0.00000 REMARK 350 BIOMT2 2 -0.866025 -0.500000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 -71.47850 REMARK 400 REMARK 400 COMPOUND REMARK 400 CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. REMARK 400 HERE, CYCLOSPORIN A IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: CYCLOSPORIN A REMARK 400 CHAIN: B, F, L, P, R REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 11 REMARK 400 DESCRIPTION: CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. REMARK 400 CYCLIZATION IS ACHIEVED BY LINKING THE N- AND REMARK 400 THE C- TERMINI. REMARK 400 REMARK 400 THE CYCLOSPORIN A IS CYCLIC PEPTIDE, A MEMBER OF IMMUNOSUPPRESSANT REMARK 400 CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: CYCLOSPORIN A REMARK 400 CHAIN: B, F, L, P, R REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. CYCLIZATION REMARK 400 IS ACHIEVED BY LINKING THE N- AND THE C- TERMINI. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH M 2030 O HOH M 2087 1.00 REMARK 500 O HOH M 2084 O HOH M 2102 1.01 REMARK 500 O HOH M 2092 O HOH M 2142 1.06 REMARK 500 O HOH M 2091 O HOH M 2139 1.18 REMARK 500 O HOH M 2106 O HOH M 2134 1.25 REMARK 500 O HOH M 2100 O HOH M 2101 1.26 REMARK 500 O HOH M 2029 O HOH M 2032 1.27 REMARK 500 O HOH M 2085 O HOH M 2136 1.28 REMARK 500 O HOH M 2169 O HOH M 2171 1.30 REMARK 500 O HOH M 2138 O HOH M 2140 1.38 REMARK 500 O HOH M 2088 O HOH M 2089 1.43 REMARK 500 O HOH M 2128 O HOH M 2129 1.45 REMARK 500 O HOH M 2099 O HOH M 2116 1.46 REMARK 500 O HOH M 2094 O HOH M 2097 1.46 REMARK 500 O HOH M 2052 O HOH M 2058 1.46 REMARK 500 O ALA O 26 O HOH O 2012 1.47 REMARK 500 O HOH M 2120 O HOH M 2125 1.51 REMARK 500 O VAL L 9 O HOH L 2007 1.52 REMARK 500 O HOH M 2082 O HOH M 2105 1.60 REMARK 500 O HOH M 2093 O HOH M 2141 1.69 REMARK 500 O HOH M 2081 O HOH M 2083 1.70 REMARK 500 O HOH O 2005 O HOH O 2033 1.71 REMARK 500 O HOH M 2117 O HOH M 2119 1.72 REMARK 500 O HOH M 2118 O HOH M 2128 1.76 REMARK 500 O HOH M 2008 O HOH M 2060 1.78 REMARK 500 O ALA L 11 O HOH L 2009 1.84 REMARK 500 OE1 GLU M 120 O HOH M 2121 1.84 REMARK 500 O HOH M 2077 O HOH M 2109 1.87 REMARK 500 NZ LYS M 82 O HOH M 2077 1.94 REMARK 500 CN SAR L 7 O HOH L 2005 1.98 REMARK 500 O HOH M 2122 O HOH M 2125 2.02 REMARK 500 OE2 GLU M 120 O HOH M 2123 2.04 REMARK 500 O HOH M 2083 O HOH M 2132 2.06 REMARK 500 OD1 ASN M 102 O HOH M 2101 2.06 REMARK 500 O HOH Q 2021 O HOH Q 2023 2.08 REMARK 500 O HOH M 2016 O HOH M 2023 2.10 REMARK 500 OE2 GLU Q 84 O HOH Q 2042 2.10 REMARK 500 NH2 ARG M 144 O HOH M 2157 2.13 REMARK 500 CB DAL L 1 O HOH M 2073 2.14 REMARK 500 O HOH L 2002 O HOH M 2071 2.14 REMARK 500 O HOH L 2004 O HOH L 2005 2.14 REMARK 500 NZ LYS Q 31 OE2 GLU Q 84 2.16 REMARK 500 OH TYR M 79 O HOH M 2073 2.16 REMARK 500 O THR M 32 O HOH M 2029 2.18 REMARK 500 CN MLE L 8 O HOH B 2002 2.18 REMARK 500 O HOH M 2111 O HOH M 2112 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 CH BMT L 5 O HOH M 2103 10554 1.94 REMARK 500 O HOH B 2003 O HOH M 2054 10554 2.11 REMARK 500 OE2 GLU S 15 OE2 GLU S 15 10664 2.11 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 MVA F 4 C BMT F 5 N 0.304 REMARK 500 GLU K 84 CG GLU K 84 CD 0.100 REMARK 500 GLY M 124 C ALY M 125 N 0.265 REMARK 500 ALY M 125 C HIS M 126 N 0.224 REMARK 500 GLU M 134 CG GLU M 134 CD 0.092 REMARK 500 GLU O 84 CD GLU O 84 OE1 0.071 REMARK 500 GLY O 124 C ALY O 125 N 0.160 REMARK 500 GLU Q 84 CG GLU Q 84 CD 0.104 REMARK 500 GLY Q 124 C ALY Q 125 N 0.201 REMARK 500 ALY Q 125 C HIS Q 126 N 0.192 REMARK 500 VAL Q 128 CB VAL Q 128 CG2 0.128 REMARK 500 MVA R 4 C BMT R 5 N 0.283 REMARK 500 GLU S 15 CG GLU S 15 CD 0.105 REMARK 500 GLU S 84 CG GLU S 84 CD 0.105 REMARK 500 GLY S 124 C ALY S 125 N 0.314 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 MVA F 4 O - C - N ANGL. DEV. = -11.1 DEGREES REMARK 500 GLY M 124 O - C - N ANGL. DEV. = -19.1 DEGREES REMARK 500 ALY M 125 O - C - N ANGL. DEV. = -12.9 DEGREES REMARK 500 ALY Q 125 O - C - N ANGL. DEV. = -18.5 DEGREES REMARK 500 ARG Q 144 NE - CZ - NH2 ANGL. DEV. = -3.2 DEGREES REMARK 500 GLY S 124 O - C - N ANGL. DEV. = -11.1 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 MLE B 2 74.41 -119.62 REMARK 500 MVA F 4 62.42 -116.09 REMARK 500 PHE K 60 -82.28 -142.26 REMARK 500 HIS K 70 16.40 56.99 REMARK 500 THR K 119 62.56 -118.61 REMARK 500 MLE L 2 69.54 -117.82 REMARK 500 ASP M 13 -71.96 43.25 REMARK 500 ARG M 55 110.29 -162.10 REMARK 500 PHE M 60 -76.96 -129.32 REMARK 500 THR M 119 55.94 -117.90 REMARK 500 LYS M 133 -63.98 -97.87 REMARK 500 PHE O 60 -71.97 -129.15 REMARK 500 HIS O 70 29.89 49.65 REMARK 500 THR O 119 73.51 -113.40 REMARK 500 ASP Q 13 54.18 37.11 REMARK 500 PHE Q 60 -73.22 -119.40 REMARK 500 HIS Q 70 19.57 59.27 REMARK 500 ASP S 13 40.10 34.84 REMARK 500 PRO S 16 129.60 -37.97 REMARK 500 PHE S 60 -77.52 -126.54 REMARK 500 ASP S 85 109.69 -59.23 REMARK 500 THR S 119 65.61 -115.47 REMARK 500 LYS S 133 -70.97 -99.36 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 MET M 1 VAL M 2 139.24 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 MVA F 4 13.77 REMARK 500 GLY M 124 24.51 REMARK 500 ALY M 125 -12.67 REMARK 500 GLY S 124 16.35 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH O2003 DISTANCE = 7.13 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN B OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN F OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN L OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN P OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN R OF CYCLOSPORIN A REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BCK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 C REMARK 900 RELATED ID: 1C5F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CSA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF E.COLI CYCLOPHILIN (F112W) COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 1CWA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 1CWB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 1CWC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 D REMARK 900 RELATED ID: 1CWH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A MODIFIED AT POSITION 7 REMARK 900 RELATED ID: 1CWI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITION 7 REMARK 900 RELATED ID: 1CWJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH NODIFIED REMARK 900 CYCLOSPORIN C AT POSITIONS 1, AND 9 REMARK 900 RELATED ID: 1CYA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WIYH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYB RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN B COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 1IKF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CTCLOSPORIN-FAB COMPLEX REMARK 900 RELATED ID: 1M63 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CALCINEURIN-CYCLOPHILIN-CYCLOSPORIN COMPLEX REMARK 900 RELATED ID: 1MF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CALCINEURIN COMPLEXED WITH HUMAN REMARK 900 CYCLOPHILIN AND CYCLOSPORIN A REMARK 900 RELATED ID: 1MIK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 6 REMARK 900 RELATED ID: 1QNG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN COMPLEXED REMARK 900 WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1QNH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN (DOUBLE REMARK 900 MUTANT) COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1XQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TRYPANOSOMA CRUZI CYCLOPHILIN COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2ESL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2OJU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN J COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2POY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM IOWA II CYCLOPHILIN A REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2RMA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2RMB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 2RMC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE CYCLOPHILIN C COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2WFJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF HUMAN CYCLOPHILIN G REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2X2C RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ACETYL-CYPA COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2X7K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PPIL1 COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2Z6W RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN D IN COMPLEX WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3BO7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOSPHILIN A FROM TOXOPLASMA GONDII REMARK 900 COMPLEXED WIT CYCLOSPORIN A REMARK 900 RELATED ID: 3CYS RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE HUMAN CYCLOSPORIN A COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3EOV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOPHILIN FROM LEISHMANIA DONOVANI COMPLEXED REMARK 900 WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1VBS RELATED DB: PDB REMARK 900 STRUCTURE OF CYCLOPHILIN COMPLEXED WITH (D) ALA CONTAINING REMARK 900 TETRAPEPTIDE REMARK 900 RELATED ID: 1OCA RELATED DB: PDB REMARK 900 HUMAN CYCLOPHILIN A, UNLIGATED, NMR, 20 STRUCTURES REMARK 900 RELATED ID: 2CYH RELATED DB: PDB REMARK 900 CYCLOPHILIN A COMPLEXED WITH DIPEPTIDE ALA- PRO REMARK 900 RELATED ID: 1VBT RELATED DB: PDB REMARK 900 STRUCTURE OF CYCLOPHILIN COMPLEXED WITH SULFUR -SUBSTITUTED REMARK 900 TETRAPEPTIDE AAPF REMARK 900 RELATED ID: 1M9E RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF CYCLOPHILIN A/ HIV-1 CA N-TERMINAL REMARK 900 DOMAIN (1-146) M- TYPE H87A COMPLEX. REMARK 900 RELATED ID: 1RMH RELATED DB: PDB REMARK 900 RECOMBINANT CYCLOPHILIN A FROM HUMAN T CELL REMARK 900 RELATED ID: 1M9C RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF CYCLOPHILIN A/ HIV-1 CA N-TERMINAL REMARK 900 DOMAIN (1-146) M- TYPE COMPLEX. REMARK 900 RELATED ID: 1M9Y RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF CYCLOPHILIN A/ HIV-1 CA N-TERMINAL REMARK 900 DOMAIN (1-146) M- TYPE H87A,G89A COMPLEX. REMARK 900 RELATED ID: 1M9F RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF CYCLOPHILIN A/ HIV-1 CA N-TERMINAL REMARK 900 DOMAIN (1-146) M- TYPE H87A,A88M COMPLEX. REMARK 900 RELATED ID: 4CYH RELATED DB: PDB REMARK 900 CYCLOPHILIN A COMPLEXED WITH DIPEPTIDE HIS- PRO REMARK 900 RELATED ID: 1W8V RELATED DB: PDB REMARK 900 ENZYMATIC AND STRUCTURAL CHARACTERIZATION OF NON PEPTIDE LIGAND REMARK 900 CYCLOPHILIN COMPLEXES REMARK 900 RELATED ID: 1AWR RELATED DB: PDB REMARK 900 CYPA COMPLEXED WITH HAGPIA REMARK 900 RELATED ID: 1NMK RELATED DB: PDB REMARK 900 THE SANGLIFEHRIN-CYCLOPHILIN INTERACTION: DEGRADATION WORK, REMARK 900 SYNTHETIC MACROCYCLIC ANALOGUES , X-RAY CRYSTAL STRUCTUREAND REMARK 900 BINDING DATA REMARK 900 RELATED ID: 1AWV RELATED DB: PDB REMARK 900 CYPA COMPLEXED WITH HVGPIA REMARK 900 RELATED ID: 1M9D RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF CYCLOPHILIN A/ HIV-1 CA N-TERMINAL REMARK 900 DOMAIN (1-146) O- TYPE CHIMERA COMPLEX. REMARK 900 RELATED ID: 2X2A RELATED DB: PDB REMARK 900 FREE ACETYL-CYPA TRIGONAL FORM REMARK 900 RELATED ID: 1AWT RELATED DB: PDB REMARK 900 SECYPA COMPLEXED WITH HAGPIA REMARK 900 RELATED ID: 2CPL RELATED DB: PDB REMARK 900 CYCLOPHILIN A REMARK 900 RELATED ID: 1FGL RELATED DB: PDB REMARK 900 CYCLOPHILIN A COMPLEXED WITH A FRAGMENT OF HIV-1 GAGPROTEIN REMARK 900 RELATED ID: 1M9X RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF CYCLOPHILIN A/ HIV-1 CA N-TERMINAL REMARK 900 DOMAIN (1-146) M- TYPE H87A,A88M,G89A COMPLEX. REMARK 900 RELATED ID: 5CYH RELATED DB: PDB REMARK 900 CYCLOPHILIN A COMPLEXED WITH DIPEPTIDE GLY- PRO REMARK 900 RELATED ID: 2X2D RELATED DB: PDB REMARK 900 ACETYL-CYPA:HIV-1 N-TERM CAPSID DOMAIN COMPLEX REMARK 900 RELATED ID: 1AK4 RELATED DB: PDB REMARK 900 HUMAN CYCLOPHILIN A BOUND TO THE AMINO- TERMINAL DOMAIN OF HIV-1 REMARK 900 CAPSID REMARK 900 RELATED ID: 2ALF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYPA MUTANT K131A REMARK 900 RELATED ID: 1AWS RELATED DB: PDB REMARK 900 SECYPA COMPLEXED WITH HAGPIA (PSEUDO-SYMMETRIC MONOMER) REMARK 900 RELATED ID: 2X25 RELATED DB: PDB REMARK 900 FREE ACETYL-CYPA ORTHORHOMBIC FORM REMARK 900 RELATED ID: 1W8L RELATED DB: PDB REMARK 900 ENZYMATIC AND STRUCTURAL CHARACTERIZATION OF NON PEPTIDE LIGAND REMARK 900 CYCLOPHILIN COMPLEXES REMARK 900 RELATED ID: 1AWU RELATED DB: PDB REMARK 900 CYPA COMPLEXED WITH HVGPIA (PSEUDO-SYMMETRIC MONOMER) REMARK 900 RELATED ID: 1W8M RELATED DB: PDB REMARK 900 ENZYMATIC AND STRUCTURAL CHARACTERISATION OF NON PEPTIDE LIGAND REMARK 900 CYCLOPHILIN COMPLEXES DBREF 2X2C K 1 165 UNP P62937 PPIA_HUMAN 1 165 DBREF 2X2C M 1 165 UNP P62937 PPIA_HUMAN 1 165 DBREF 2X2C O 1 165 UNP P62937 PPIA_HUMAN 1 165 DBREF 2X2C Q 1 165 UNP P62937 PPIA_HUMAN 1 165 DBREF 2X2C S 1 165 UNP P62937 PPIA_HUMAN 1 165 DBREF 2X2C B 1 11 NOR NOR00033 NOR00033 1 11 DBREF 2X2C F 1 11 NOR NOR00033 NOR00033 1 11 DBREF 2X2C L 1 11 NOR NOR00033 NOR00033 1 11 DBREF 2X2C P 1 11 NOR NOR00033 NOR00033 1 11 DBREF 2X2C R 1 11 NOR NOR00033 NOR00033 1 11 SEQRES 1 B 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 F 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 K 165 MET VAL ASN PRO THR VAL PHE PHE ASP ILE ALA VAL ASP SEQRES 2 K 165 GLY GLU PRO LEU GLY ARG VAL SER PHE GLU LEU PHE ALA SEQRES 3 K 165 ASP LYS VAL PRO LYS THR ALA GLU ASN PHE ARG ALA LEU SEQRES 4 K 165 SER THR GLY GLU LYS GLY PHE GLY TYR LYS GLY SER CYS SEQRES 5 K 165 PHE HIS ARG ILE ILE PRO GLY PHE MET CYS GLN GLY GLY SEQRES 6 K 165 ASP PHE THR ARG HIS ASN GLY THR GLY GLY LYS SER ILE SEQRES 7 K 165 TYR GLY GLU LYS PHE GLU ASP GLU ASN PHE ILE LEU LYS SEQRES 8 K 165 HIS THR GLY PRO GLY ILE LEU SER MET ALA ASN ALA GLY SEQRES 9 K 165 PRO ASN THR ASN GLY SER GLN PHE PHE ILE CYS THR ALA SEQRES 10 K 165 LYS THR GLU TRP LEU ASP GLY ALY HIS VAL VAL PHE GLY SEQRES 11 K 165 LYS VAL LYS GLU GLY MET ASN ILE VAL GLU ALA MET GLU SEQRES 12 K 165 ARG PHE GLY SER ARG ASN GLY LYS THR SER LYS LYS ILE SEQRES 13 K 165 THR ILE ALA ASP CYS GLY GLN LEU GLU SEQRES 1 L 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 M 165 MET VAL ASN PRO THR VAL PHE PHE ASP ILE ALA VAL ASP SEQRES 2 M 165 GLY GLU PRO LEU GLY ARG VAL SER PHE GLU LEU PHE ALA SEQRES 3 M 165 ASP LYS VAL PRO LYS THR ALA GLU ASN PHE ARG ALA LEU SEQRES 4 M 165 SER THR GLY GLU LYS GLY PHE GLY TYR LYS GLY SER CYS SEQRES 5 M 165 PHE HIS ARG ILE ILE PRO GLY PHE MET CYS GLN GLY GLY SEQRES 6 M 165 ASP PHE THR ARG HIS ASN GLY THR GLY GLY LYS SER ILE SEQRES 7 M 165 TYR GLY GLU LYS PHE GLU ASP GLU ASN PHE ILE LEU LYS SEQRES 8 M 165 HIS THR GLY PRO GLY ILE LEU SER MET ALA ASN ALA GLY SEQRES 9 M 165 PRO ASN THR ASN GLY SER GLN PHE PHE ILE CYS THR ALA SEQRES 10 M 165 LYS THR GLU TRP LEU ASP GLY ALY HIS VAL VAL PHE GLY SEQRES 11 M 165 LYS VAL LYS GLU GLY MET ASN ILE VAL GLU ALA MET GLU SEQRES 12 M 165 ARG PHE GLY SER ARG ASN GLY LYS THR SER LYS LYS ILE SEQRES 13 M 165 THR ILE ALA ASP CYS GLY GLN LEU GLU SEQRES 1 O 165 MET VAL ASN PRO THR VAL PHE PHE ASP ILE ALA VAL ASP SEQRES 2 O 165 GLY GLU PRO LEU GLY ARG VAL SER PHE GLU LEU PHE ALA SEQRES 3 O 165 ASP LYS VAL PRO LYS THR ALA GLU ASN PHE ARG ALA LEU SEQRES 4 O 165 SER THR GLY GLU LYS GLY PHE GLY TYR LYS GLY SER CYS SEQRES 5 O 165 PHE HIS ARG ILE ILE PRO GLY PHE MET CYS GLN GLY GLY SEQRES 6 O 165 ASP PHE THR ARG HIS ASN GLY THR GLY GLY LYS SER ILE SEQRES 7 O 165 TYR GLY GLU LYS PHE GLU ASP GLU ASN PHE ILE LEU LYS SEQRES 8 O 165 HIS THR GLY PRO GLY ILE LEU SER MET ALA ASN ALA GLY SEQRES 9 O 165 PRO ASN THR ASN GLY SER GLN PHE PHE ILE CYS THR ALA SEQRES 10 O 165 LYS THR GLU TRP LEU ASP GLY ALY HIS VAL VAL PHE GLY SEQRES 11 O 165 LYS VAL LYS GLU GLY MET ASN ILE VAL GLU ALA MET GLU SEQRES 12 O 165 ARG PHE GLY SER ARG ASN GLY LYS THR SER LYS LYS ILE SEQRES 13 O 165 THR ILE ALA ASP CYS GLY GLN LEU GLU SEQRES 1 P 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 Q 165 MET VAL ASN PRO THR VAL PHE PHE ASP ILE ALA VAL ASP SEQRES 2 Q 165 GLY GLU PRO LEU GLY ARG VAL SER PHE GLU LEU PHE ALA SEQRES 3 Q 165 ASP LYS VAL PRO LYS THR ALA GLU ASN PHE ARG ALA LEU SEQRES 4 Q 165 SER THR GLY GLU LYS GLY PHE GLY TYR LYS GLY SER CYS SEQRES 5 Q 165 PHE HIS ARG ILE ILE PRO GLY PHE MET CYS GLN GLY GLY SEQRES 6 Q 165 ASP PHE THR ARG HIS ASN GLY THR GLY GLY LYS SER ILE SEQRES 7 Q 165 TYR GLY GLU LYS PHE GLU ASP GLU ASN PHE ILE LEU LYS SEQRES 8 Q 165 HIS THR GLY PRO GLY ILE LEU SER MET ALA ASN ALA GLY SEQRES 9 Q 165 PRO ASN THR ASN GLY SER GLN PHE PHE ILE CYS THR ALA SEQRES 10 Q 165 LYS THR GLU TRP LEU ASP GLY ALY HIS VAL VAL PHE GLY SEQRES 11 Q 165 LYS VAL LYS GLU GLY MET ASN ILE VAL GLU ALA MET GLU SEQRES 12 Q 165 ARG PHE GLY SER ARG ASN GLY LYS THR SER LYS LYS ILE SEQRES 13 Q 165 THR ILE ALA ASP CYS GLY GLN LEU GLU SEQRES 1 R 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 S 165 MET VAL ASN PRO THR VAL PHE PHE ASP ILE ALA VAL ASP SEQRES 2 S 165 GLY GLU PRO LEU GLY ARG VAL SER PHE GLU LEU PHE ALA SEQRES 3 S 165 ASP LYS VAL PRO LYS THR ALA GLU ASN PHE ARG ALA LEU SEQRES 4 S 165 SER THR GLY GLU LYS GLY PHE GLY TYR LYS GLY SER CYS SEQRES 5 S 165 PHE HIS ARG ILE ILE PRO GLY PHE MET CYS GLN GLY GLY SEQRES 6 S 165 ASP PHE THR ARG HIS ASN GLY THR GLY GLY LYS SER ILE SEQRES 7 S 165 TYR GLY GLU LYS PHE GLU ASP GLU ASN PHE ILE LEU LYS SEQRES 8 S 165 HIS THR GLY PRO GLY ILE LEU SER MET ALA ASN ALA GLY SEQRES 9 S 165 PRO ASN THR ASN GLY SER GLN PHE PHE ILE CYS THR ALA SEQRES 10 S 165 LYS THR GLU TRP LEU ASP GLY ALY HIS VAL VAL PHE GLY SEQRES 11 S 165 LYS VAL LYS GLU GLY MET ASN ILE VAL GLU ALA MET GLU SEQRES 12 S 165 ARG PHE GLY SER ARG ASN GLY LYS THR SER LYS LYS ILE SEQRES 13 S 165 THR ILE ALA ASP CYS GLY GLN LEU GLU MODRES 2X2C MLE B 2 LEU N-METHYLLEUCINE MODRES 2X2C MLE B 3 LEU N-METHYLLEUCINE MODRES 2X2C MVA B 4 VAL N-METHYLVALINE MODRES 2X2C BMT B 5 THR MODRES 2X2C ABA B 6 ALA ALPHA-AMINOBUTYRIC ACID MODRES 2X2C SAR B 7 GLY SARCOSINE MODRES 2X2C MLE B 8 LEU N-METHYLLEUCINE MODRES 2X2C MLE B 10 LEU N-METHYLLEUCINE MODRES 2X2C MLE F 2 LEU N-METHYLLEUCINE MODRES 2X2C MLE F 3 LEU N-METHYLLEUCINE MODRES 2X2C MVA F 4 VAL N-METHYLVALINE MODRES 2X2C BMT F 5 THR MODRES 2X2C ABA F 6 ALA ALPHA-AMINOBUTYRIC ACID MODRES 2X2C SAR F 7 GLY SARCOSINE MODRES 2X2C MLE F 8 LEU N-METHYLLEUCINE MODRES 2X2C MLE F 10 LEU N-METHYLLEUCINE MODRES 2X2C ALY K 125 LYS N(6)-ACETYLLYSINE MODRES 2X2C MLE L 2 LEU N-METHYLLEUCINE MODRES 2X2C MLE L 3 LEU N-METHYLLEUCINE MODRES 2X2C MVA L 4 VAL N-METHYLVALINE MODRES 2X2C BMT L 5 THR MODRES 2X2C ABA L 6 ALA ALPHA-AMINOBUTYRIC ACID MODRES 2X2C SAR L 7 GLY SARCOSINE MODRES 2X2C MLE L 8 LEU N-METHYLLEUCINE MODRES 2X2C MLE L 10 LEU N-METHYLLEUCINE MODRES 2X2C ALY M 125 LYS N(6)-ACETYLLYSINE MODRES 2X2C ALY O 125 LYS N(6)-ACETYLLYSINE MODRES 2X2C MLE P 2 LEU N-METHYLLEUCINE MODRES 2X2C MLE P 3 LEU N-METHYLLEUCINE MODRES 2X2C MVA P 4 VAL N-METHYLVALINE MODRES 2X2C BMT P 5 THR MODRES 2X2C ABA P 6 ALA ALPHA-AMINOBUTYRIC ACID MODRES 2X2C SAR P 7 GLY SARCOSINE MODRES 2X2C MLE P 8 LEU N-METHYLLEUCINE MODRES 2X2C MLE P 10 LEU N-METHYLLEUCINE MODRES 2X2C ALY Q 125 LYS N(6)-ACETYLLYSINE MODRES 2X2C MLE R 2 LEU N-METHYLLEUCINE MODRES 2X2C MLE R 3 LEU N-METHYLLEUCINE MODRES 2X2C MVA R 4 VAL N-METHYLVALINE MODRES 2X2C BMT R 5 THR MODRES 2X2C ABA R 6 ALA ALPHA-AMINOBUTYRIC ACID MODRES 2X2C SAR R 7 GLY SARCOSINE MODRES 2X2C MLE R 8 LEU N-METHYLLEUCINE MODRES 2X2C MLE R 10 LEU N-METHYLLEUCINE MODRES 2X2C ALY S 125 LYS N(6)-ACETYLLYSINE HET DAL B 1 5 HET MLE B 2 9 HET MLE B 3 9 HET MVA B 4 8 HET BMT B 5 13 HET ABA B 6 6 HET SAR B 7 5 HET MLE B 8 9 HET MLE B 10 9 HET DAL F 1 5 HET MLE F 2 9 HET MLE F 3 9 HET MVA F 4 8 HET BMT F 5 13 HET ABA F 6 6 HET SAR F 7 5 HET MLE F 8 9 HET MLE F 10 9 HET ALY K 125 12 HET DAL L 1 5 HET MLE L 2 9 HET MLE L 3 9 HET MVA L 4 8 HET BMT L 5 13 HET ABA L 6 6 HET SAR L 7 5 HET MLE L 8 9 HET MLE L 10 9 HET ALY M 125 12 HET ALY O 125 12 HET DAL P 1 5 HET MLE P 2 9 HET MLE P 3 9 HET MVA P 4 8 HET BMT P 5 13 HET ABA P 6 6 HET SAR P 7 5 HET MLE P 8 9 HET MLE P 10 9 HET ALY Q 125 12 HET DAL R 1 5 HET MLE R 2 9 HET MLE R 3 9 HET MVA R 4 8 HET BMT R 5 13 HET ABA R 6 6 HET SAR R 7 5 HET MLE R 8 9 HET MLE R 10 9 HET ALY S 125 12 HETNAM DAL D-ALANINE HETNAM MLE N-METHYLLEUCINE HETNAM MVA N-METHYLVALINE HETNAM BMT 4-METHYL-4-[(E)-2-BUTENYL]-4,N-METHYL-THREONINE HETNAM ABA ALPHA-AMINOBUTYRIC ACID HETNAM SAR SARCOSINE HETNAM ALY N(6)-ACETYLLYSINE FORMUL 1 DAL 5(C3 H7 N O2) FORMUL 1 MLE 20(C7 H15 N O2) FORMUL 1 MVA 5(C6 H13 N O2) FORMUL 1 BMT 5(C10 H19 N O3) FORMUL 1 ABA 5(C4 H9 N O2) FORMUL 1 SAR 5(C3 H7 N O2) FORMUL 3 ALY 5(C8 H16 N2 O3) FORMUL 11 HOH *497(H2 O) HELIX 1 1 VAL K 29 GLY K 42 1 14 HELIX 2 2 THR K 119 ASP K 123 5 5 HELIX 3 3 GLY K 135 PHE K 145 1 11 HELIX 4 4 VAL M 29 GLY M 42 1 14 HELIX 5 5 THR M 119 ASP M 123 5 5 HELIX 6 6 GLY M 135 ARG M 144 1 10 HELIX 7 7 VAL O 29 GLY O 42 1 14 HELIX 8 8 THR O 119 ASP O 123 5 5 HELIX 9 9 GLY O 135 ARG O 144 1 10 HELIX 10 10 VAL Q 29 GLY Q 42 1 14 HELIX 11 11 THR Q 119 ASP Q 123 5 5 HELIX 12 12 GLY Q 135 ARG Q 144 1 10 HELIX 13 13 VAL S 29 GLY S 42 1 14 HELIX 14 14 THR S 119 ASP S 123 5 5 HELIX 15 15 GLY S 135 ARG S 144 1 10 SHEET 1 KA 8 ARG K 55 ILE K 57 0 SHEET 2 KA 8 MET K 61 GLY K 64 -1 O MET K 61 N ILE K 57 SHEET 3 KA 8 PHE K 112 CYS K 115 -1 O PHE K 112 N GLY K 64 SHEET 4 KA 8 ILE K 97 MET K 100 -1 O ILE K 97 N CYS K 115 SHEET 5 KA 8 VAL K 128 GLU K 134 -1 N PHE K 129 O LEU K 98 SHEET 6 KA 8 GLU K 15 LEU K 24 -1 O SER K 21 N LYS K 133 SHEET 7 KA 8 THR K 5 VAL K 12 -1 O VAL K 6 N PHE K 22 SHEET 8 KA 8 ILE K 156 GLN K 163 -1 O THR K 157 N ALA K 11 SHEET 1 MA 8 PHE M 53 ILE M 57 0 SHEET 2 MA 8 MET M 61 GLY M 64 -1 O MET M 61 N ILE M 57 SHEET 3 MA 8 PHE M 112 CYS M 115 -1 O PHE M 112 N GLY M 64 SHEET 4 MA 8 ILE M 97 MET M 100 -1 O ILE M 97 N CYS M 115 SHEET 5 MA 8 VAL M 128 VAL M 132 -1 N PHE M 129 O LEU M 98 SHEET 6 MA 8 GLU M 15 LEU M 24 -1 O GLU M 23 N LYS M 131 SHEET 7 MA 8 THR M 5 VAL M 12 -1 O VAL M 6 N PHE M 22 SHEET 8 MA 8 ILE M 156 GLN M 163 -1 O THR M 157 N ALA M 11 SHEET 1 OA 8 ARG O 55 ILE O 57 0 SHEET 2 OA 8 MET O 61 GLY O 64 -1 O MET O 61 N ILE O 57 SHEET 3 OA 8 PHE O 112 CYS O 115 -1 O PHE O 112 N GLY O 64 SHEET 4 OA 8 ILE O 97 MET O 100 -1 O ILE O 97 N CYS O 115 SHEET 5 OA 8 VAL O 128 GLU O 134 -1 N PHE O 129 O LEU O 98 SHEET 6 OA 8 GLU O 15 LEU O 24 -1 O SER O 21 N LYS O 133 SHEET 7 OA 8 THR O 5 VAL O 12 -1 O VAL O 6 N PHE O 22 SHEET 8 OA 8 ILE O 156 GLN O 163 -1 O THR O 157 N ALA O 11 SHEET 1 QA 8 ARG Q 55 ILE Q 57 0 SHEET 2 QA 8 MET Q 61 GLY Q 64 -1 O MET Q 61 N ILE Q 57 SHEET 3 QA 8 PHE Q 112 CYS Q 115 -1 O PHE Q 112 N GLY Q 64 SHEET 4 QA 8 ILE Q 97 MET Q 100 -1 O ILE Q 97 N CYS Q 115 SHEET 5 QA 8 VAL Q 128 GLU Q 134 -1 N PHE Q 129 O LEU Q 98 SHEET 6 QA 8 GLU Q 15 LEU Q 24 -1 O SER Q 21 N LYS Q 133 SHEET 7 QA 8 THR Q 5 VAL Q 12 -1 O VAL Q 6 N PHE Q 22 SHEET 8 QA 8 ILE Q 156 GLN Q 163 -1 O THR Q 157 N ALA Q 11 SHEET 1 SA 8 ARG S 55 ILE S 57 0 SHEET 2 SA 8 MET S 61 GLY S 64 -1 O MET S 61 N ILE S 57 SHEET 3 SA 8 PHE S 112 CYS S 115 -1 O PHE S 112 N GLY S 64 SHEET 4 SA 8 ILE S 97 MET S 100 -1 O ILE S 97 N CYS S 115 SHEET 5 SA 8 VAL S 128 VAL S 132 -1 N PHE S 129 O LEU S 98 SHEET 6 SA 8 GLU S 15 LEU S 24 -1 O GLU S 23 N LYS S 131 SHEET 7 SA 8 THR S 5 VAL S 12 -1 O VAL S 6 N PHE S 22 SHEET 8 SA 8 ILE S 156 GLN S 163 -1 O THR S 157 N ALA S 11 LINK C DAL B 1 N MLE B 2 1555 1555 1.34 LINK N DAL B 1 C ALA B 11 1555 1555 1.32 LINK C MLE B 2 N MLE B 3 1555 1555 1.34 LINK C MLE B 3 N MVA B 4 1555 1555 1.34 LINK C MVA B 4 N BMT B 5 1555 1555 1.67 LINK C BMT B 5 N ABA B 6 1555 1555 1.32 LINK C ABA B 6 N SAR B 7 1555 1555 1.33 LINK C SAR B 7 N MLE B 8 1555 1555 1.34 LINK C MLE B 8 N VAL B 9 1555 1555 1.33 LINK C VAL B 9 N MLE B 10 1555 1555 1.34 LINK C MLE B 10 N ALA B 11 1555 1555 1.33 LINK N DAL F 1 C ALA F 11 1555 1555 1.34 LINK C DAL F 1 N MLE F 2 1555 1555 1.36 LINK C MLE F 2 N MLE F 3 1555 1555 1.33 LINK C MLE F 3 N MVA F 4 1555 1555 1.34 LINK C MVA F 4 N BMT F 5 1555 1555 1.64 LINK C BMT F 5 N ABA F 6 1555 1555 1.35 LINK C ABA F 6 N SAR F 7 1555 1555 1.34 LINK C SAR F 7 N MLE F 8 1555 1555 1.32 LINK C MLE F 8 N VAL F 9 1555 1555 1.32 LINK C VAL F 9 N MLE F 10 1555 1555 1.33 LINK C MLE F 10 N ALA F 11 1555 1555 1.33 LINK C ALY K 125 N HIS K 126 1555 1555 1.75 LINK N DAL L 1 C ALA L 11 1555 1555 1.34 LINK C DAL L 1 N MLE L 2 1555 1555 1.35 LINK C MLE L 2 N MLE L 3 1555 1555 1.33 LINK C MLE L 3 N MVA L 4 1555 1555 1.35 LINK C MVA L 4 N BMT L 5 1555 1555 1.70 LINK C BMT L 5 N ABA L 6 1555 1555 1.32 LINK C ABA L 6 N SAR L 7 1555 1555 1.34 LINK C SAR L 7 N MLE L 8 1555 1555 1.34 LINK C MLE L 8 N VAL L 9 1555 1555 1.34 LINK C VAL L 9 N MLE L 10 1555 1555 1.32 LINK C MLE L 10 N ALA L 11 1555 1555 1.33 LINK C GLY M 124 N ALY M 125 1555 1555 1.60 LINK C ALY M 125 N HIS M 126 1555 1555 1.56 LINK C GLY O 124 N ALY O 125 1555 1555 1.50 LINK C ALY O 125 N HIS O 126 1555 1555 1.71 LINK C DAL P 1 N MLE P 2 1555 1555 1.34 LINK N DAL P 1 C ALA P 11 1555 1555 1.33 LINK C MLE P 2 N MLE P 3 1555 1555 1.33 LINK C MLE P 3 N MVA P 4 1555 1555 1.34 LINK C MVA P 4 N BMT P 5 1555 1555 1.67 LINK C BMT P 5 N ABA P 6 1555 1555 1.32 LINK C ABA P 6 N SAR P 7 1555 1555 1.33 LINK C SAR P 7 N MLE P 8 1555 1555 1.33 LINK C MLE P 8 N VAL P 9 1555 1555 1.31 LINK C VAL P 9 N MLE P 10 1555 1555 1.32 LINK C MLE P 10 N ALA P 11 1555 1555 1.33 LINK C GLY Q 124 N ALY Q 125 1555 1555 1.54 LINK C ALY Q 125 N HIS Q 126 1555 1555 1.53 LINK N DAL R 1 C ALA R 11 1555 1555 1.32 LINK C DAL R 1 N MLE R 2 1555 1555 1.35 LINK C MLE R 2 N MLE R 3 1555 1555 1.34 LINK C MLE R 3 N MVA R 4 1555 1555 1.35 LINK C MVA R 4 N BMT R 5 1555 1555 1.62 LINK C BMT R 5 N ABA R 6 1555 1555 1.35 LINK C ABA R 6 N SAR R 7 1555 1555 1.34 LINK C SAR R 7 N MLE R 8 1555 1555 1.32 LINK C MLE R 8 N VAL R 9 1555 1555 1.32 LINK C VAL R 9 N MLE R 10 1555 1555 1.32 LINK C MLE R 10 N ALA R 11 1555 1555 1.32 LINK C GLY S 124 N ALY S 125 1555 1555 1.65 LINK C ALY S 125 N HIS S 126 1555 1555 1.67 SITE 1 AC1 22 HOH B2001 HOH B2002 HOH B2003 THR K 73 SITE 2 AC1 22 GLU K 81 ALA K 103 HOH K2020 ABA L 6 SITE 3 AC1 22 SAR L 7 ARG M 55 PHE M 60 GLN M 63 SITE 4 AC1 22 GLY M 72 ALA M 101 ASN M 102 ALA M 103 SITE 5 AC1 22 GLN M 111 PHE M 113 TRP M 121 HIS M 126 SITE 6 AC1 22 PRO O 30 TYR O 79 SITE 1 AC2 22 HOH F2001 HOH F2002 MET K 1 HOH K2006 SITE 2 AC2 22 THR O 73 GLU O 81 ALA O 103 HOH O2037 SITE 3 AC2 22 ABA P 6 SAR P 7 MLE P 8 ARG S 55 SITE 4 AC2 22 PHE S 60 GLN S 63 GLY S 72 ALA S 101 SITE 5 AC2 22 ASN S 102 ALA S 103 GLN S 111 PHE S 113 SITE 6 AC2 22 TRP S 121 HIS S 126 SITE 1 AC3 32 SAR B 7 MLE B 8 HOH B2002 ARG K 55 SITE 2 AC3 32 PHE K 60 GLN K 63 GLY K 72 ALA K 101 SITE 3 AC3 32 ASN K 102 ALA K 103 GLN K 111 PHE K 113 SITE 4 AC3 32 TRP K 121 HIS K 126 HOH L2001 HOH L2003 SITE 5 AC3 32 HOH L2005 HOH L2006 HOH L2007 HOH L2008 SITE 6 AC3 32 HOH L2009 MET M 1 PRO M 30 THR M 73 SITE 7 AC3 32 TYR M 79 GLU M 81 ALA M 103 HOH M2066 SITE 8 AC3 32 HOH M2067 HOH M2073 HOH M2103 HOH M2112 SITE 1 AC4 21 ABA F 6 SAR F 7 MLE F 8 ARG O 55 SITE 2 AC4 21 PHE O 60 GLN O 63 GLY O 72 ALA O 101 SITE 3 AC4 21 ASN O 102 ALA O 103 GLN O 111 PHE O 113 SITE 4 AC4 21 TRP O 121 HIS O 126 HOH P2002 PRO Q 30 SITE 5 AC4 21 LYS Q 31 THR S 73 GLU S 81 ALA S 103 SITE 6 AC4 21 HOH S2036 SITE 1 AC5 14 ARG Q 55 PHE Q 60 GLN Q 63 GLY Q 72 SITE 2 AC5 14 THR Q 73 GLU Q 81 ALA Q 101 ASN Q 102 SITE 3 AC5 14 ALA Q 103 GLN Q 111 PHE Q 113 TRP Q 121 SITE 4 AC5 14 HIS Q 126 MET S 1 CRYST1 107.429 107.429 428.871 90.00 90.00 120.00 P 61 2 2 60 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.009308 0.005374 0.000000 0.00000 SCALE2 0.000000 0.010748 0.000000 0.00000 SCALE3 0.000000 0.000000 0.002332 0.00000 HETATM 1 N DAL B 1 36.475 0.593 -54.905 1.00 35.41 N HETATM 2 CA DAL B 1 36.418 -0.604 -55.762 1.00 33.63 C HETATM 3 CB DAL B 1 37.366 -0.482 -56.902 1.00 33.03 C HETATM 4 C DAL B 1 35.014 -0.768 -56.298 1.00 33.09 C HETATM 5 O DAL B 1 34.355 0.230 -56.585 1.00 33.05 O HETATM 6 N MLE B 2 34.530 -2.016 -56.418 1.00 31.26 N HETATM 7 CN MLE B 2 35.294 -3.228 -56.068 1.00 31.05 C HETATM 8 CA MLE B 2 33.105 -2.220 -56.738 1.00 28.61 C HETATM 9 CB MLE B 2 32.989 -2.936 -58.072 1.00 27.54 C HETATM 10 CG MLE B 2 33.612 -2.182 -59.245 1.00 28.66 C HETATM 11 CD1 MLE B 2 32.999 -0.778 -59.529 1.00 29.19 C HETATM 12 CD2 MLE B 2 33.506 -3.070 -60.490 1.00 21.28 C HETATM 13 C MLE B 2 32.338 -2.996 -55.681 1.00 27.19 C HETATM 14 O MLE B 2 32.049 -4.159 -55.893 1.00 24.78 O HETATM 15 N MLE B 3 32.017 -2.388 -54.536 1.00 26.69 N HETATM 16 CN MLE B 3 32.440 -1.015 -54.233 1.00 25.49 C HETATM 17 CA MLE B 3 31.338 -3.169 -53.476 1.00 26.07 C HETATM 18 CB MLE B 3 32.049 -3.000 -52.144 1.00 25.58 C HETATM 19 CG MLE B 3 33.467 -3.600 -52.061 1.00 26.48 C HETATM 20 CD1 MLE B 3 33.524 -5.068 -52.505 1.00 24.13 C HETATM 21 CD2 MLE B 3 34.021 -3.532 -50.642 1.00 26.52 C HETATM 22 C MLE B 3 29.892 -2.720 -53.407 1.00 27.39 C HETATM 23 O MLE B 3 29.578 -1.625 -53.930 1.00 29.05 O HETATM 24 N MVA B 4 28.978 -3.495 -52.802 1.00 26.65 N HETATM 25 CN MVA B 4 29.242 -4.838 -52.329 1.00 25.98 C HETATM 26 CA MVA B 4 27.614 -2.981 -52.663 1.00 25.66 C HETATM 27 CB MVA B 4 26.578 -3.818 -53.340 1.00 25.51 C HETATM 28 CG1 MVA B 4 27.033 -4.167 -54.733 1.00 23.73 C HETATM 29 CG2 MVA B 4 25.263 -3.001 -53.331 1.00 25.41 C HETATM 30 C MVA B 4 27.176 -2.886 -51.255 1.00 26.24 C HETATM 31 O MVA B 4 26.660 -3.859 -50.694 1.00 27.62 O HETATM 32 N BMT B 5 27.951 -1.782 -50.272 1.00 27.83 N HETATM 33 CN BMT B 5 28.337 -0.598 -51.061 1.00 28.06 C HETATM 34 CA BMT B 5 27.574 -1.799 -48.874 1.00 26.98 C HETATM 35 C BMT B 5 26.432 -0.851 -48.531 1.00 28.24 C HETATM 36 O BMT B 5 25.838 -0.202 -49.406 1.00 29.36 O HETATM 37 CB BMT B 5 28.881 -1.556 -48.091 1.00 26.51 C HETATM 38 OG1 BMT B 5 29.273 -0.275 -48.402 1.00 24.69 O HETATM 39 CG2 BMT B 5 30.065 -2.535 -48.372 1.00 25.07 C HETATM 40 CD1 BMT B 5 29.595 -3.986 -48.452 1.00 22.41 C HETATM 41 CD2 BMT B 5 31.260 -2.418 -47.394 1.00 23.31 C HETATM 42 CE BMT B 5 31.076 -2.805 -45.932 1.00 23.74 C HETATM 43 CZ BMT B 5 31.286 -1.851 -44.836 1.00 25.30 C HETATM 44 CH BMT B 5 30.863 -2.247 -43.444 1.00 29.06 C HETATM 45 N ABA B 6 26.084 -0.795 -47.256 1.00 28.41 N HETATM 46 CA ABA B 6 24.980 -0.014 -46.785 1.00 28.22 C HETATM 47 C ABA B 6 25.552 0.864 -45.691 1.00 28.86 C HETATM 48 O ABA B 6 25.413 0.540 -44.542 1.00 27.82 O HETATM 49 CB ABA B 6 23.925 -0.969 -46.183 1.00 28.21 C HETATM 50 CG ABA B 6 23.348 -1.949 -47.211 1.00 24.98 C HETATM 51 N SAR B 7 26.223 1.955 -46.046 1.00 30.64 N HETATM 52 CA SAR B 7 26.683 2.905 -45.033 1.00 31.63 C HETATM 53 C SAR B 7 28.119 3.341 -45.159 1.00 32.72 C HETATM 54 O SAR B 7 28.352 4.500 -45.426 1.00 34.78 O HETATM 55 CN SAR B 7 26.445 2.307 -47.424 1.00 30.06 C HETATM 56 N MLE B 8 29.100 2.455 -44.948 1.00 33.61 N HETATM 57 CN MLE B 8 28.773 1.049 -44.830 1.00 32.59 C HETATM 58 CA MLE B 8 30.509 2.790 -45.351 1.00 32.87 C HETATM 59 CB MLE B 8 31.565 2.180 -44.459 1.00 32.53 C HETATM 60 CG MLE B 8 32.628 3.098 -43.874 1.00 33.54 C HETATM 61 CD1 MLE B 8 32.916 4.374 -44.652 1.00 34.73 C HETATM 62 CD2 MLE B 8 33.892 2.266 -43.659 1.00 29.14 C HETATM 63 C MLE B 8 30.713 2.245 -46.743 1.00 32.87 C HETATM 64 O MLE B 8 30.915 1.017 -46.928 1.00 31.77 O